27 Sep 2024 | 10:43 AM UTC
Ghana: Elevated dengue fever activity reported in multiple areas in September /update 1
Elevated dengue fever activity reported in multiple areas in Ghana in September. Avoid mosquito bites.
Health authorities have reported elevated dengue fever activity in multiple areas across Ghana, with an additional 1,139 cases reported between July 20-Sept. 23, bringing the total case count to 1,713 cases (206 confirmed cases) since Jan. 1. This is compared to 18 cases reported in 2023. Eight of the country’s 16 regions are affected. Health officials are conducting enhanced surveillance, advising citizens to take preventive measures against mosquito bites, increasing public awareness, and urging health staff to be vigilant for symptoms. This report represents the most complete data available as of Sept. 27.
If you have previously been infected with dengue fever, consult with your physician regarding vaccination. Avoid mosquito bites and remove standing water to reduce the number of biting mosquitoes. Seek medical attention if symptoms develop within two weeks of being in affected areas. Do not use aspirin or ibuprofen products if dengue fever is suspected, as these could exacerbate bleeding tendencies associated with the disease.
Dengue has been present in Ghana, with past cases and recent active infections confirming its ongoing presence in the country. The risk is highest during the rainy seasons spanning from May-September in the northern part and April-July and September-November in the southern part.
Dengue fever is transmitted through the bite of an infected mosquito. Risk of infection is often highest in urban and semi-urban areas. Symptoms of dengue fever include a sudden onset of fever and at least one of the following: severe headache, severe pain behind the eyes, muscle and/or joint pain, rash, easy bruising, and/or nose or gum bleeding. Symptoms typically appear 5-7 days after being bitten, but can develop up to 10 days after exposure. Dengue fever can progress to a more severe form known as dengue hemorrhagic fever (DHF). DHF can be fatal if it is not recognized and treated in a timely manner. There are two dengue fever vaccines, Dengvaxia (CYD-TDV) and Qdenga (TAK-003). Dengvaxia is only recommended for individuals with a history of dengue infection and who live in dengue-endemic countries or areas. Qdenga is recommended for use in children aged 6-16 in settings with high dengue burden and transmission intensity. Check with your healthcare provider if dengue vaccination is needed.
